AJMC December 9, 2025
Zachary Contreras of Sharp Health Plan discusses how predictive tools, artificial intelligence-driven analytics, and digital monitoring can help identify treatment-resistant depression early, enabling timely intervention with dextromethorphan-bupropion and reducing clinical and economic burden.
Zachary Contreras, Director of Pharmacy Benefits at Sharp Health Plan, discussed insights from AMCP Nexus regarding the management of patients with treatment-resistant major depressive disorder (MDD) initiating dextromethorphan-bupropion (DM-BUP).1 The majority of patients starting DM-BUP had previously received 2 or more antidepressant therapies, highlighting the complexity of this population and the need for earlier identification of treatment resistance to prevent escalating costs and poor clinical outcomes.
Contreras emphasized the potential of predictive and proactive screening tools to identify patients at high risk for treatment-resistant depression....
Today's Sponsors
Today's Sponsor